Literature DB >> 7011938

"Carcinoid" tumor of the breast. A variant of conventional breast cancer?

J B Taxy, A S Tischler, S J Insalaco, H Battifora.   

Abstract

A breast tumor with the morphologic features of a carcinoid tumor and containing large amounts of estrogen receptor protein was associated with areas of typical in situ and infiltrating lobular carcinoma. The carcinoid areas were argyrophilic and ultrastructurally contained electron dense granules on which silver grains were localized. Of 21 other examples of ordinary breast cancer, five showed histologic similarities to carcinoid tumors. Focal argyrophilia was observed in 11 invasive tumors. The presence of argyrophilic granules could not be correlated with the presence of "neurosecretory" granules, although groups of such granules were found in one case of in situ lobular carcinoma. Argyrophilic and "neurosecretory" granules imply the presence of hormonal substances, although in breast tumors these granules have not yet been chemically or immunochemically characterized. Until such evidence becomes available it would appear that most cases reported as primary carcinoid tumors of the breast have much more in common with conventional breast cancer than with the usual carcinoid tumor. Within this context it can be acknowledged that some breast cancers may focally exhibit a carcinoid-like differentiation.

Entities:  

Mesh:

Year:  1981        PMID: 7011938     DOI: 10.1016/s0046-8177(81)80104-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

1.  Endocrine variant of ductal carcinoma in situ of breast: ultrastructural and light microscopical study.

Authors:  M T Ashworth; M T Haqqani
Journal:  J Clin Pathol       Date:  1986-12       Impact factor: 3.411

2.  Sex steroid receptor expression in 'carcinoid' tumours of the breast.

Authors:  C A Birsak; P J Janssen; C C van Vroonhoven; J L Peterse; T H van der Kwast
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Immunocytochemical reactivity of breast cancer tissue with antibodies to neuron-specific enolase and an adenocarcinoma-associated glycolipid antigen.

Authors:  H Ingelman-Sundberg; B Wikström; N Stormy; P Sundelin; A Hjerpe
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

4.  Chromogranin A and chromogranin B in noninvasive and invasive breast carcinoma.

Authors:  Noriko Kimura; Ryuichi Yoshida; Shin-ichiro Shiraishi; Monika Pilichowska; Noriaki Ohuchi
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

5.  Resected case of carcinoid tumor of the liver metastatic from the breast.

Authors:  M Imamura; H Yamauchi; T Namiki
Journal:  J Gastroenterol       Date:  1995-06       Impact factor: 7.527

6.  Small cell neuroendocrine (oat cell) carcinoma of the male breast. Immunocytochemical and ultrastructural investigations.

Authors:  G Jundt; A Schulz; P U Heitz; M Osborn
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

Review 7.  Carcinomas of the breast with endocrine differentiation: a review.

Authors:  H M Maluf; F C Koerner
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

Review 8.  Working formulation of neuroendocrine tumors of the skin and breast.

Authors:  Sofia Asioli; Maria Pia Foschini; Riccardo Masetti; Vincenzo Eusebi
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

9.  Pancreatic Neuroendocrine Carcinoma Metastatic to the Breast as Part of the Multiple Endocrine Neoplasia Type 1 Syndrome.

Authors:  Isabelle Treilleux; Gilles Freyer; Eric Tabone; Catherine Chassagne-Clement; Alain Bremond; Christiane Bailly
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

10.  Chromogranin A and B gene expression in carcinomas of the breast. Correlation of immunocytochemical, immunoblot, and hybridization analyses.

Authors:  A Pagani; M Papotti; H Höfler; R Weiler; H Winkler; G Bussolati
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.